News Summary
Ono Pharma is set to lay off 83 employees at its Cambridge headquarters by June 30. This decision follows economic challenges in the biopharmaceutical industry, despite recent successes like the FDA approval of Romvimza. The layoffs have raised concerns about project impacts and job security as Ono tries to navigate this difficult period.
Boston Braces for Job Cuts as Ono Pharma Plans Layoffs
In a surprising turn of events, Ono Pharma, the U.S. branch of the long-established Japanese pharmaceutical company, is letting go of 83 employees at its Cambridge headquarters. This news comes as part of a Workers Adjustment Retraining Notice that was filed in Massachusetts on April 22, outlining plans for these layoffs to take effect by June 30. It’s a bittersweet moment for a company that has been expanding its presence in the U.S. since its inception here in 2020.
A Little Background on Ono Pharma
Founded way back in 1717 in Osaka, Japan, Ono Pharmaceuticals has a rich history of medical contributions. Despite its long-standing roots, the company’s journey in the American market is relatively new. In 2020, Ono made its initial foray into the U.S., and by 2021, it had shifted its headquarters from New Jersey to the bustling innovation hub of Cambridge.
Currently, Ono Pharma operates 20 locations across five different countries, including another site in San Francisco, California. The company is known for developing drugs targeting various specialties, notably in oncology, immunology, and neurology. With such a diverse portfolio, Ono has been a relevant player in the biopharmaceutical field. However, like many in the industry, it is not immune to the economic challenges that are surfacing right now.
Challenges in the Biopharma Industry
The upcoming layoffs at Ono Pharma are part of a larger trend in the biopharmaceutical sector, which has seen many companies also cutting back on staff. As the industry faces economic pressures, these layoffs raise concerns about how they might impact ongoing projects and vital clinical trials. With 83 jobs on the line, it’s a potential setback for the company as it works to advance its drug developments.
Recent Successes Amid Setbacks
Another striking difference is that Turalio, developed by Daiichi Sankyo, comes with warnings for hepatotoxicity, while Romvimza does not have such warnings. Ono secured rights to Romvimza through an impressive $2.4 billion acquisition of Deciphera Pharmaceuticals, which is also based in Boston. This step underscores Ono’s commitment to developing innovative treatments, even as they face tough choices regarding workforce reduction.
The Future for Ono Pharma and Its Employees
In the meantime, the anticipation for Romvimza’s availability in the U.S. market mounts, especially after clinical trials showcased a remarkable 40% objective response rate compared to a strikingly low 0% in placebo groups. If all goes well, Romvimza could soon be providing relief for patients in need. As circumstances unfold, both the employees and the broader biopharma community keep a watchful eye.
Deeper Dive: News & Info About This Topic
HERE Resources
Boston Life Sciences Real Estate Market in Turmoil
Thermo Fisher Scientific Cuts 300 Jobs in Massachusetts
CVS Health Shuts Down Accountable Care Business in Wellesley, Job Losses Expected
Massachusetts Job Uncertainty as Bristol Myers Squibb Cuts Costs
Massachusetts Cannabis Industry Faces Tough Times
Additional Resources
- MassLive: Pharmaceutical Company to Cut 83 Boston Area Jobs
- BioSpace: Ono’s FDA Rare Cancer Approval
- Stat News: Ono Pharmaceutical to Acquire Deciphera Pharma
- Google Search: Ono Pharmaceuticals
- BioSpace: Layoff Tracker
- Encyclopedia Britannica: Pharmaceutical Industry
Author: STAFF HERE BOSTON WRITER
BOSTON STAFF WRITER The BOSTON STAFF WRITER represents the experienced team at HEREBoston.com, your go-to source for actionable local news and information in Boston, Suffolk County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Boston Marathon, Head of the Charles Regatta, and Boston Harborfest. Our coverage extends to key organizations like the Greater Boston Chamber of Commerce and Associated Industries of Massachusetts, plus leading businesses in finance, biotech, and insurance that power the local economy such as Fidelity Investments, Biogen, and Liberty Mutual Insurance. As part of the broader HERE network, we provide comprehensive, credible insights into Massachusetts's dynamic landscape.
